Literature DB >> 11245467

Gene expression patterns associated with the metastatic phenotype in rodent and human tumors.

A Nestl1, O D Von Stein, K Zatloukal, W G Thies, P Herrlich, M Hofmann, J P Sleeman.   

Abstract

Using subtractive technology, we have generated metastasis-associated gene expression profiles for rat mammary and pancreatic adenocarcinomas. Several genes whose expression is thought to be related to tumor progression such as c-Met, urokinase-type plasminogen activator receptor, ezrin, HMG-1, oncomodulin, cathepsin, and caveolin were thereby isolated. Half of the metastasis-associated clones showed no significant homology to genes with known function. Notably, several of the metastasis-associated clones were also expressed in metastatic lines but not in nonmetastatic lines of other tumor models. Furthermore, in situ hybridization using selected clones documents the relevance of these results for human cancer because strong expression in tumor cells including metastases was detected in human colorectal cancer samples and, to a lesser extent, in mammary cancer samples. These data support the concept that tumors express a "metastatic program" of genes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11245467

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  43 in total

1.  CD44 is required for two consecutive steps in HGF/c-Met signaling.

Authors:  Véronique Orian-Rousseau; Linfeng Chen; Jonathan P Sleeman; Peter Herrlich; Helmut Ponta
Journal:  Genes Dev       Date:  2002-12-01       Impact factor: 11.361

2.  Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas.

Authors:  K Völp; M-L Brezniceanu; S Bösser; T Brabletz; T Kirchner; D Göttel; S Joos; M Zörnig
Journal:  Gut       Date:  2005-08-23       Impact factor: 23.059

Review 3.  High mobility group A: a novel biomarker and therapeutic target in pancreatic adenocarcinoma.

Authors:  S S Liau; E Whang
Journal:  Surgeon       Date:  2009-10       Impact factor: 2.392

Review 4.  Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer.

Authors:  Geetha Srikrishna; Hudson H Freeze
Journal:  Neoplasia       Date:  2009-07       Impact factor: 5.715

Review 5.  Tumour biological aspects of CD24, a mucin-like adhesion molecule.

Authors:  G Kristiansen; M Sammar; P Altevogt
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

Review 6.  CD44 in cancer progression: adhesion, migration and growth regulation.

Authors:  R Marhaba; M Zöller
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

7.  Epigenetic drugs can stimulate metastasis through enhanced expression of the pro-metastatic Ezrin gene.

Authors:  Yanlin Yu; Pingyao Zeng; Jingbo Xiong; Ziyang Liu; Shelley L Berger; Glenn Merlino
Journal:  PLoS One       Date:  2010-09-13       Impact factor: 3.240

Review 8.  Cancer stem cells in colorectal cancer from pathogenesis to therapy: controversies and perspectives.

Authors:  Caterina Fanali; Donatella Lucchetti; Marisa Farina; Maddalena Corbi; Valerio Cufino; Achille Cittadini; Alessandro Sgambato
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

9.  Regulation of Son of sevenless by the membrane-actin linker protein ezrin.

Authors:  Katja J Geissler; M Juliane Jung; Lars Björn Riecken; Tobias Sperka; Yan Cui; Stephan Schacke; Ulrike Merkel; Robby Markwart; Ignacio Rubio; Manuel E Than; Constanze Breithaupt; Sebastian Peuker; Reinhard Seifert; Ulrich Benjamin Kaupp; Peter Herrlich; Helen Morrison
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

10.  Downregulation of E-cadherin is an essential event in activating beta-catenin/Tcf-dependent transcription and expression of its target genes in Pdcd4 knockdown cells.

Authors:  Q Wang; Z-X Sun; H Allgayer; H-S Yang
Journal:  Oncogene       Date:  2009-09-28       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.